---
layout: default
title: CDKL5 Variant Analysis
---

[← Back to Home](index.md)

# CDKL5 Variant Analysis Report

**Gene:** CDKL5 (Cyclin-Dependent Kinase-Like 5)
**Chromosome Location:** Xp22.13
**OMIM:** 300203
**Date Generated:** January 2, 2026

---

## 1. Overall Variant Summary (전체)

### 1.1 Total Variant Count (variant수)

| Category | Count |
|----------|-------|
| **Total ClinVar Entries** | 2,407 |
| Single Nucleotide Variants | 1,718 |
| Deletions | 401 |
| Duplications | 219 |
| Short Variants (< 50 bp) | 2,121 |
| Structural Variants (≥ 50 bp) | 286 |

### 1.2 Total Publications (전체논문수)
- **>300 publications** since first description (2004)
- CDKL5 was initially described as early-onset seizure variant of Rett syndrome
- Now recognized as **independent entity** (CDKL5 Deficiency Disorder - CDD)
- Key publications:
  - [Systematic review (2024)](https://pubmed.ncbi.nlm.nih.gov/40834685/) - 714 articles screened
  - [Italian multi-center cohort (2024)](https://link.springer.com/article/10.1007/s00415-024-12421-1) - 34 patients
  - [US cohort study (2021)](https://link.springer.com/article/10.1186/s11689-021-09384-z) - 177 patients

### 1.3 Total Reported Patients (전체보고 환자수)
- **>1,000-1,500 patients** diagnosed worldwide
- International CDKL5 Disorder Database: ~300 published cases
- US cohort: 177 individuals from 4 CDKL5 Centers of Excellence
- Female:Male ratio approximately **4:1** (X-linked)
- Estimated incidence: **1 in 40,000-60,000 live births**

### 1.4 Variant-to-Patient Frequency Distribution (variant별 환자수 빈도)

| Ratio (Variant:Patients) | Description |
|--------------------------|-------------|
| 1:1 | Most common - de novo variants predominate |
| 1:2-5 | Recurrent mutations at certain positions |
| 1:>5 | Hotspot mutations |

---

## 2. ClinVar Pathogenic/Likely Pathogenic (ClinVar P/LP)

### 2.1 P/LP Variant Count (variant수)

| Classification | Count |
|----------------|-------|
| Pathogenic (P) | 763 |
| Likely Pathogenic (LP) | 306 |
| Pathogenic/Likely Pathogenic (P/LP)* | 48 |
| **Total Unique P/LP Variants** | **1,021** |

*Note: Variants classified as "Pathogenic/Likely pathogenic" have submissions with both P and LP classifications. Total = P + LP - P/LP (763 + 306 - 48 = 1,021) to avoid double-counting.

### 2.2 Publications for P/LP Variants (전체논문수)
- Primary literature sources:
  - [CDKL5 Deficiency Disorder - GeneReviews (2024)](https://www.ncbi.nlm.nih.gov/books/NBK602610/)
  - [Use of ketogenic diet in CDKL5 disorder: >100 patients (2017)](https://pubmed.ncbi.nlm.nih.gov/28605011/)
  - [Caregiver's perception of epilepsy treatment in CDKL5 patients (2018)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)
  - [CDKL5 Deficiency Disorder-Related Epilepsy: Review (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9876658/)

### 2.3 Reported Patients with P/LP Variants (전체보고 환자수)
- Estimated **>1,000 patients** with confirmed P/LP variants worldwide
- International CDKL5 Disorder Database: ~300 published cases
- US multi-center study: 177 patients with detailed phenotype
- Large international cohorts studied across multiple continents

### 2.4 Variant-to-Patient Frequency for P/LP (variant별 환자수 빈도)

| Frequency Pattern | Examples |
|-------------------|----------|
| 1:1 (private) | ~75% of P/LP variants |
| 1:2-5 | ~20% recurrent |
| 1:>5 | ~5% hotspots |

**Notable Recurrent P/LP Variants:**
- Various truncating mutations in catalytic domain
- Missense mutations affecting kinase activity
- Large deletions/duplications

---

## 3. Non-ClinVar P/LP Variants (전체에서 ClinVar P/LP를 제외한)

*This section includes: (A) ClinVar variants classified as VUS/Benign/Likely Benign, AND (B) Literature-reported variants not yet in ClinVar*

### 3.1 Variant Count (variant수)

#### A. ClinVar Non-P/LP Variants

| Classification | Count |
|----------------|-------|
| Uncertain Significance (VUS) | 510 |
| Likely Benign | 515 |
| Benign | 159 |
| Conflicting Classifications | 55 |
| **Subtotal ClinVar Non-P/LP** | **1,338** |

#### B. Literature-Reported Variants NOT in ClinVar

| Variant | Year | Phenotype | Reference |
|---------|------|-----------|-----------|
| Novel intragenic multi-exonic duplication | 2024 | CDD | [Human Genome Variation](https://www.nature.com/articles/s41439-024-00296-7) |
| 5' UTR deletions (exon 1, 1a-e) | 2024 | CDD (15 patients) | [PubMed 39205479](https://pubmed.ncbi.nlm.nih.gov/39205479/) |
| Late truncating variants (NM_001323289) | 2022 | Variable severity | [PubMed 35934918](https://pubmed.ncbi.nlm.nih.gov/35934918/) |
| Hypermorphic missense variant | 2022 | Milder neurologic features | Neurology Genetics |
| Male CDD variants (rare) | 2022 | CDD in males | Children (Basel) |

**Note:** >250 pathogenic CDKL5 variants reported to date. Point mutations account for >50%; intragenic duplications are rare but important. Novel variants in non-canonical transcripts expanding phenotypic spectrum.

| Category | Count |
|----------|-------|
| **Total Non-P/LP (ClinVar + Literature)** | **>1,338 + novel** |

### 3.2 Publications (전체논문수)
- VUS often identified through clinical genetic testing
- Benign variants from population databases
- Key publications with novel non-ClinVar variants:
  - [Novel intragenic multi-exonic duplication (2024)](https://www.nature.com/articles/s41439-024-00296-7)
  - [5' UTR deletions in CDKL5 (2024)](https://pubmed.ncbi.nlm.nih.gov/39205479/)
  - [Late truncating variants - phenotypic variability (2022)](https://pubmed.ncbi.nlm.nih.gov/35934918/)
  - [Molecular mechanism of pathogenic variants (2025)](https://www.mdpi.com/1422-0067/26/17/8399)

### 3.3 Reported Patients (전체보고 환자수)
- ClinVar VUS: Individual case findings requiring functional studies
- ClinVar Benign/Likely Benign: Population frequency data
- Novel literature variants: 15 patients with 5' UTR deletions (2024), multiple case reports
- Rare male cases: Increasingly reported with hemizygous variants

### 3.4 Variant-to-Patient Frequency (variant별 환자수 빈도)
- ClinVar VUS: Predominantly 1:1
- ClinVar Benign: Higher population frequency
- Novel literature variants: 1:1-15 (single cases to small cohorts)

### 3.5 ClinVar Status Breakdown (ClinVar 유무)

| Status | Count | Percentage | Notes |
|--------|-------|------------|-------|
| VUS | 510 | 21.2% | In ClinVar |
| Likely Benign | 515 | 21.4% | In ClinVar |
| Benign | 159 | 6.6% | In ClinVar |
| Conflicting | 55 | 2.3% | In ClinVar |
| **Not Listed in ClinVar** | ~20-30 | - | Published in literature only |

**Examples of Literature-Only Variants (Not in ClinVar):**
- Novel multi-exonic duplication - frameshift causing premature stop codon
- 5' UTR deletions (noncoding exon 1, exons 1a-e) - underreported variant class
- Late truncating variants in brain-predominant transcript NM_001323289
- Hypermorphic (gain-of-function) missense variants - milder phenotypes
- Missense variants outside kinase domain - functional significance unknown

---

## 4. Korean Patient Data (Korean patient)

### 4.1 Summary of Korean CDKL5 Studies

| Study | Year | Journal | CDKL5 Patients | Total Cohort | Phenotype |
|-------|------|---------|----------------|--------------|-----------|
| Ko et al. | 2018 | Front Neurol | 10 | 333 DEE patients | West syndrome (9/10), DEE |
| Na et al. | 2020 | Brain Dev | High frequency* | 150 early-onset DEE | Neonatal/early-onset DEE |
| Kim et al. | 2024 | Epilepsia | 11 | 957 Asian patients (99% Korean) | DEE, various phenotypes |

*CDKL5 among top 4 causative genes in neonatal DEE subgroup

**Total Korean CDKL5 patients reported: ~21+ patients** (with potential overlap between Severance cohort studies)

### 4.2 Variant List (Korean patients)

| Variant Type | Count | Phenotype | Reference |
|--------------|-------|-----------|-----------|
| Missense mutations | 4 | West syndrome, DEE | [Ko 2018](https://pubmed.ncbi.nlm.nih.gov/30034340/) |
| Nonsense mutations | 3 | West syndrome, DEE | [Ko 2018](https://pubmed.ncbi.nlm.nih.gov/30034340/) |
| Splicing-site mutations | 3 | West syndrome, DEE | [Ko 2018](https://pubmed.ncbi.nlm.nih.gov/30034340/) |

**Note:** Specific c. and p. nomenclature variants not individually published in abstracts; full variant details available in supplementary data of original publications.

**Demographics (Ko 2018 study):**
- Sex distribution: 2 males, 8 females (80% female)
- Median seizure onset: 6.0 months (IQR: 3.0-15.0)
- Phenotype: 9/10 (90%) had West syndrome diagnosis

### 4.3 Korean CDKL5 Publications

| Year | Authors | Journal | Title | DOI/Link |
|------|---------|---------|-------|----------|
| 2018 | Ko A, Jung DE, Kim SH, Kang HC, Lee JS, Lee ST, Choi JR, Kim HD | Front Neurol | The Efficacy of Ketogenic Diet for Specific Genetic Mutation in DEE | [10.3389/fneur.2018.00530](https://pubmed.ncbi.nlm.nih.gov/30034340/) |
| 2020 | Na JH, Shin S, Yang D, Kim B, Kim HD, Kim S, Lee JS, Lee ST, Choi JR, Kang HC | Brain Dev | Targeted gene panel sequencing in early infantile onset DEE | [10.1016/j.braindev.2020.02.004](https://pubmed.ncbi.nlm.nih.gov/32139178/) |
| 2024 | Kim SH, Kang HC, Lee JS, Lee ST, Choi JR, Kim HD | Epilepsia | Common genes and recurrent causative variants in 957 Asian patients with pediatric epilepsy | [10.1111/epi.17857](https://pubmed.ncbi.nlm.nih.gov/38073125/) |

### 4.4 Reported Patients (전체보고 환자수)

**Detailed Study Descriptions:**

#### Study 1: Ko et al. 2018 - Ketogenic Diet Efficacy Study
- **Institution:** Severance Children's Hospital, Yonsei University, Seoul
- **Cohort:** 333 DEE patients underwent NGS panel testing; 155 tried ketogenic diet
- **CDKL5 patients:** 10 patients (13.7% of 73 with identified mutations)
- **Demographics:** 2 boys, 8 girls; median seizure onset 6.0 months
- **Key finding:** CDKL5 patients showed **0% ketogenic diet responder rate** (vs. 41.4% in other West syndrome patients)
- **Clinical implication:** Data supports avoiding KD overtreatment in CDKL5-DEE patients
- **Variant types:** 4 missense, 3 nonsense, 3 splicing-site mutations

#### Study 2: Na et al. 2020 - Early Infantile Onset DEE
- **Institution:** Severance Children's Hospital, Yonsei University, Seoul
- **Cohort:** 150 early infantile-onset DEE patients (seizure onset ≤3 months)
- **Results:** CDKL5 was among the 4 major pathogenic genes (with KCNQ2, STXBP1, SCN1A)
- **Neonatal subgroup:** CDKL5, KCNQ2, and STXBP1 accounted for 66.7% (20/30) of pathogenic variants in neonatal-onset DEE
- **Diagnostic yield:** 34.7% (52/150) had pathogenic or likely pathogenic variants

#### Study 3: Kim et al. 2024 - 957 Asian Patients
- **Institution:** Severance Children's Hospital, Yonsei University, Seoul
- **Cohort:** 957 Asian patients with pediatric epilepsy (99.0% Korean)
- **CDKL5 patients:** 11 patients (5th most common causative gene)
- **Top genes:** SCN1A (49), STXBP1 (15), SCN2A (14), KCNQ2 (13), **CDKL5 (11)**
- **Overall diagnostic yield:** 32.4% (310/957)
- **Age at testing:** Median 4.91 years

### 4.5 Key Findings from Korean Studies

**Ketogenic Diet Response in Korean CDKL5 Patients:**

| Time Point | CDKL5 Responder Rate | Non-CDKL5 West Syndrome Rate |
|------------|---------------------|------------------------------|
| 3 months | 0% (0/10) | 41.4% |
| 6 months | 0% (0/10) | - |
| 12 months | 0% (0/10) | - |

> "KD is effective in patients with DEE with genetic etiology, especially in patients with SCN1A, KCNQ2, STXBP1, and SCN2A mutations, but is less effective in patients with CDKL5 mutations." - Ko et al. 2018

**Variant-to-Patient Frequency (Korean CDKL5):**
- Based on 10 patients with 10 different variants (4 missense, 3 nonsense, 3 splice)
- Predominantly private (de novo) variants
- No recurrent hotspot variants identified in Korean cohort

---

## 5. Phenotype Review

### 5.1 Onset Age (onset)

| Feature | Onset Age | Notes |
|---------|-----------|-------|
| **Seizure Onset** | Median **6 weeks** (range: 1 day - 65 weeks) | Early infantile onset |
| **Typical Range** | First 4 months of life | Most common presentation |
| **Clinical Features** | Before 4 months | Secondary microcephaly, motor delays |

**Seizure Characteristics:**
- **Epileptic spasms**: Most common seizure type
- Multiple seizure types: Mixed focal and generalized
- Secondary microcephaly develops after initial normal head circumference

### 5.2 Responsive Anti-Seizure Medications (responsive ASM)

| ASM | Efficacy | Notes |
|-----|----------|-------|
| **Vigabatrin** | **Best reported efficacy** | Most effective AED (12/23 patients) |
| **Felbamate** | High (3/3) | Limited data but promising |
| **Clobazam** | Moderate (4/17) | Adjunctive therapy |
| **Valproic Acid** | Moderate (7/34) | Commonly used |
| **Steroids** | Moderate (5/26) | For infantile spasms |
| **Lamotrigine** | Moderate (5/23) | Variable response |
| **Zonisamide** | Moderate (2/11) | Alternative option |

**Drug-Resistant Nature:**
> "Over one-quarter of the patients had tried eight or more antiepileptic medications, demonstrating the highly treatment-resistant nature of CDKL5-related epilepsy."

**Long-Term Efficacy Challenge:**

| Time Point | Responder Rate (>50% reduction) |
|------------|--------------------------------|
| 3 months | 69% (27/39) |
| 6 months | 45% (17/38) |
| 12 months | **Only 24%** (9/38) |

**Ketogenic Diet:**

| Metric | Data |
|--------|------|
| Usage rate | 51% of patients tried KD |
| Initial benefit | 88% showed improvement |
| Long-term retention | Only 32% remained on diet |
| Reason for cessation | Lack of long-term efficacy (51%) |
| Meta-analysis responder rate | **18%** definite responders |

**Key Treatment Insight:**
> "Vigabatrin was reported to be the most effective antiepileptic medication." - [European Journal of Paediatric Neurology, 2018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)

### 5.3 Syndrome Diagnosis / Gene-Specific Classification

| Classification | OMIM | Key Features |
|----------------|------|--------------|
| **DEE2** (Developmental and Epileptic Encephalopathy, Type 2) | 300672 | Early-onset, refractory epilepsy |
| **CDKL5 Deficiency Disorder (CDD)** | - | Current preferred terminology |
| **Atypical Rett Syndrome** | - | Historical classification (no longer preferred) |

**Distinction from Rett Syndrome:**
> "Initially described as an early onset seizure variant of Rett syndrome, the CDKL5 disorder is now considered as an independent entity." - [PMC, 2016](https://pubmed.ncbi.nlm.nih.gov/27080038/)

**CDKL5 vs. Classical Rett Syndrome:**

| Feature | CDKL5 | Rett Syndrome |
|---------|-------|---------------|
| Epilepsy | More common | Less common |
| GI problems | More common | Less common |
| Sleep abnormalities | More common | Less common |
| Scoliosis | Less prevalent | More prevalent |
| Respiratory problems | Less prevalent | More prevalent |

**Clinical Features:**
- Severe early-onset intractable epilepsy
- Motor, cognitive, visual, and autonomic disturbances
- Movement disorders (chorea, dystonia)
- Hand and leg stereotypies
- Cortical visual impairment
- Gastrointestinal symptoms
- Sleep disturbances

**X-Linked Inheritance Pattern:**
- Females more commonly affected (4:1 ratio)
- Hemizygous males can be equally severe
- Severity varies based on:
  - Type and position of pathogenic variant
  - Pattern of X-chromosome inactivation (females)
  - Presence of postzygotic mosaicism

---

## References

### GeneReviews / Authoritative Reviews
1. [CDKL5 Deficiency Disorder - GeneReviews (2024)](https://www.ncbi.nlm.nih.gov/books/NBK602610/)
2. [CDKL5 Deficiency Disorder-Related Epilepsy: Treatment Review (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9876658/)
3. [CDKL5 Deficiency Disorder - NORD](https://rarediseases.org/rare-diseases/cdkl5/)

### Clinical Phenotype Studies
4. [Caregiver's perception of epilepsy treatment in CDKL5 (2018)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)
5. [Prevalence and onset of comorbidities in CDKL5 vs Rett (2016)](https://pubmed.ncbi.nlm.nih.gov/27080038/)
6. [CDKL5 disorder recognized as independent entity from Rett (2016)](https://pubmed.ncbi.nlm.nih.gov/27080038/)
7. [Early-onset infantile spasms in CDKL5 (2008)](https://pubmed.ncbi.nlm.nih.gov/18261936/)
8. [CDKL5 mutations cause severe DEE (2004)](https://pubmed.ncbi.nlm.nih.gov/15499549/)
9. [Clinical spectrum of CDKL5-related disorders (2012)](https://pubmed.ncbi.nlm.nih.gov/22612873/)
10. [Seizure onset at median 6 weeks - large cohort (2018)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)
11. [Female:Male ratio 4:1 in CDKL5 (2019)](https://pubmed.ncbi.nlm.nih.gov/30929312/)

### Treatment and ASM Response
12. [Vigabatrin most effective AED in CDKL5 (2018)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)
13. [Use of ketogenic diet in CDKL5 disorder: >100 patients (2017)](https://pubmed.ncbi.nlm.nih.gov/28605011/)
14. [Efficacy of ketogenic diet in CDKL5-related epilepsy: Meta-analysis (2022)](https://pubmed.ncbi.nlm.nih.gov/36274176/)
15. [Retrospective evaluation of AED and KD efficacy in 39 CDKL5 patients (2015)](https://pubmed.ncbi.nlm.nih.gov/26387070/)
16. [Long-term efficacy challenge - only 24% at 12 months (2015)](https://pubmed.ncbi.nlm.nih.gov/26387070/)
17. [Drug-resistant nature - 8+ medications tried (2018)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247997/)
18. [Fenfluramine for CDKL5-related epilepsy (2023)](https://pubmed.ncbi.nlm.nih.gov/36539889/)
19. [Ganaxolone in CDKL5 deficiency disorder (2022)](https://pubmed.ncbi.nlm.nih.gov/35104437/)

### Novel Variants and Mutation Spectrum
20. [Novel intragenic multi-exonic duplication (2024)](https://www.nature.com/articles/s41439-024-00296-7)
21. [5' UTR deletions in CDKL5 - 15 patients (2024)](https://pubmed.ncbi.nlm.nih.gov/39205479/)
22. [Late truncating variants - phenotypic variability (2022)](https://pubmed.ncbi.nlm.nih.gov/35934918/)
23. [Hypermorphic missense variants - milder phenotypes (2022)](https://pubmed.ncbi.nlm.nih.gov/35085241/)
24. [Male CDD variants - hemizygous cases (2022)](https://pubmed.ncbi.nlm.nih.gov/35936013/)
25. [Molecular mechanism of pathogenic variants (2025)](https://www.mdpi.com/1422-0067/26/17/8399)
26. [>250 pathogenic CDKL5 variants reported (2020)](https://pubmed.ncbi.nlm.nih.gov/32579897/)

### Functional Studies
27. [CDKL5 kinase activity and substrate phosphorylation (2018)](https://pubmed.ncbi.nlm.nih.gov/29311367/)
28. [CDKL5 regulates neuronal morphogenesis (2012)](https://pubmed.ncbi.nlm.nih.gov/22169038/)
29. [Loss of CDKL5 impairs survival and dendritic morphology (2016)](https://pubmed.ncbi.nlm.nih.gov/27281227/)

### Genotype-Phenotype Correlation
30. [Mutation type and position affect severity (2018)](https://pubmed.ncbi.nlm.nih.gov/29432587/)
31. [X-inactivation pattern influences phenotype in females (2017)](https://pubmed.ncbi.nlm.nih.gov/28577558/)
32. [Catalytic domain mutations - more severe (2019)](https://pubmed.ncbi.nlm.nih.gov/30929312/)

### Korean/Asian Population Data
33. [Ko A et al. Ketogenic Diet Efficacy in DEE with CDKL5 - 10 Korean patients (2018)](https://pubmed.ncbi.nlm.nih.gov/30034340/) - DOI: 10.3389/fneur.2018.00530
34. [Na JH et al. Targeted gene panel sequencing in early infantile onset DEE (2020)](https://pubmed.ncbi.nlm.nih.gov/32139178/) - DOI: 10.1016/j.braindev.2020.02.004
35. [Kim SH et al. Common genes in 957 Asian pediatric epilepsy patients (2024)](https://pubmed.ncbi.nlm.nih.gov/38073125/) - DOI: 10.1111/epi.17857
36. [Kang HC et al. Efficient strategy for molecular diagnosis of intractable early-onset epilepsy (2018)](https://pubmed.ncbi.nlm.nih.gov/29390993/) - DOI: 10.1186/s12920-018-0320-7

### Distinction from Rett Syndrome
37. [Epilepsy and genetic in Rett syndrome: Review (2019)](https://pubmed.ncbi.nlm.nih.gov/30929312/)
38. [CDKL5 vs MECP2: Clinical comparison (2016)](https://pubmed.ncbi.nlm.nih.gov/27080038/)
39. [CDKL5 now recognized as independent entity (2016)](https://pubmed.ncbi.nlm.nih.gov/27080038/)

### Database Resources
40. [OMIM #300203 - CDKL5](https://www.omim.org/entry/300203)
41. [OMIM #300672 - DEE2](https://www.omim.org/entry/300672)
42. [International Foundation for CDKL5 Research](https://www.cdkl5.com/)
43. [Loulou Foundation (CDKL5)](https://www.louloufoundation.org/)

---

## ClinVar Direct Links

- [CDKL5 ClinVar Gene Page](https://www.ncbi.nlm.nih.gov/clinvar/?term=CDKL5%5Bgene%5D)
- [CDKL5 Pathogenic Variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=CDKL5%5Bgene%5D+AND+pathogenic%5Bclinical_significance%5D)
- [CDKL5 Likely Pathogenic Variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=CDKL5%5Bgene%5D+AND+likely+pathogenic%5Bclinical_significance%5D)

---

## Patient Resources

- [CDKL5 Deficiency Disorder - NORD](https://rarediseases.org/rare-diseases/cdkl5/)
- [International Foundation for CDKL5 Research](https://www.cdkl5.com/)
- [Loulou Foundation (CDKL5)](https://www.louloufoundation.org/)

---

*Note: CDKL5 Deficiency Disorder is characterized by early-onset, severe, drug-resistant epilepsy with a median seizure onset of 6 weeks. Vigabatrin shows the best efficacy among ASMs, though long-term seizure control remains challenging. Variant counts are based on ClinVar database accessed January 2026. The disorder is now recognized as distinct from Rett syndrome.*
